RouteOne
VC Fund
Farmington Hills, United States
RouteOne is a free web-based credit application management system created to streamline the F&I process for finance sources.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries RouteOne invests in
Stages RouteOne invests in
Countries RouteOne invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Bill Duhamel
|
|||
Chris Irving
|
|||
Justin Oesterle
|
|||
2 more contacts available
Investment Focus
Industry
- Biopharma 1 (50%)
- Life Science 1 (50%)
- Therapeutics 1 (50%)
- Biotechnology 1 (50%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Bill Duhamel
Managing Member
|
Managing Member | Total investments: 1 | Find email | |
|
Chris Irving
Chief Information Officer
|
Chief Information Officer | Total investments: 0 | Find email | |
|
Justin Oesterle
CEO
|
CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
OneSource
|
OneSource is a biopharmaceutical company that delivers affordable treatments to patients in both emerging and developed markets. It provides a one-stop-shop with comprehensive capabilities from cell line and process development through to scale up, cGMP manufacturing, and filling/finishing of proteins and peptides. Offer services at everystage of the development life cycle, from pre-clinical and clinical development to commercial Supply. At Stelis BioSource™, we assure customers of CDMO/CMO services our deep commitment to quality, service, and compliance. | $125M / Series C / Mar 19, 2021 | |
|
OneSource
|
OneSource is a biopharmaceutical company that delivers affordable treatments to patients in both emerging and developed markets. It provides a one-stop-shop with comprehensive capabilities from cell line and process development through to scale up, cGMP manufacturing, and filling/finishing of proteins and peptides. Offer services at everystage of the development life cycle, from pre-clinical and clinical development to commercial Supply. At Stelis BioSource™, we assure customers of CDMO/CMO services our deep commitment to quality, service, and compliance. | $125M / Series C / Mar 19, 2021 |
Co-Investors
TPG Growth
4 deals together
Think Investments
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does RouteOne invest in?
RouteOne invests primarily in Biopharma, Life Science and Therapeutics startups, most often at Series C stage. Most of the 2 investments tracked by Shizune back companies in India. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact RouteOne?
Public channels for RouteOne include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at RouteOne?
The team at RouteOne includes Bill Duhamel (Managing Member), Chris Irving (Chief Information Officer) and Justin Oesterle (CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
